Keros Therapeutics (KROS) Income towards Parent Company (2019 - 2025)

Keros Therapeutics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$23.5 million for Q4 2025.

• Quarterly Income towards Parent Company rose 49.03% year-over-year to -$23.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $87.0 million (up 146.44% YoY) and the FY2025 annual result came in at $87.0 million, up 146.44% from the prior year.
• Income towards Parent Company was -$23.5 million for Q4 2025 at Keros Therapeutics, down from -$7.3 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $148.5 million in Q1 2025 and bottomed at -$91.4 million in Q2 2023.
• A 5-year average of -$25.9 million and a median of -$28.5 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 328.21% — and 2025, when it jumped 444.32%.
• Keros Therapeutics' Income towards Parent Company stood at -$6.9 million in 2021, then tumbled by 328.21% to -$29.7 million in 2022, then plunged by 53.36% to -$45.6 million in 2023, then slipped by 0.99% to -$46.0 million in 2024, then surged by 49.03% to -$23.5 million in 2025.
• Business Quant data shows KROS's Income towards Parent Company at -$23.5 million in Q4 2025, -$7.3 million in Q3 2025, and -$30.7 million in Q2 2025.